Improving Health, Health Care and Quality of Life

DaVita HealthCare Partners Inc. 3rd Quarter 2013 Results

DENVER--(BUSINESS WIRE)--Nov. 5, 2013-- DaVita HealthCare Partners Inc. (NYSE: DVA) today announced results for the quarter ended September 30, 2013. Adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months endedSeptember 30, 2013 was $211.0 million and $605.3 million, or $0.98 and $2.82 per share, respectively, excluding a loss contingency reserve. In addition, adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2013 excluded a contingent earn-out obligation adjustment. Income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2013 including these items was $136.6 million and $407.9 million, or $0.64 per share and $1.90 per share, respectively.

Adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2012 was $147.5 million and $438.6 million, or $0.76and $2.28 per share, respectively, excluding transaction expenses associated with the acquisition of HCP, debt refinancing charges and a legal settlement and related expenses. Income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months endedSeptember 30, 2012 including these items was $144.7 million and $380.0 million, or $0.75 and $1.98per share, respectively.

Financial and operating highlights include:

  • Cash Flow: For the rolling twelve months ended September 30, 2013, operating cash flow was $1.62 billionand free cash flow was $1.24 billion. For the three months ended September 30, 2013, operating cash flow was$733 million and free cash flow was $643 million. Operating cash flow in the third quarter of 2013 benefited from the timing of compensation payments, other working capital items and cash taxes. For a definition of free cash flow see Note 4 to the reconciliations of non-GAAP measures.
  • Adjusted Operating Income: Adjusted operating income for the three and nine months ended September 30, 2013 was $482 million and $1.41 billion, respectively, which is operating income adjusted for a loss contingency reserve, a contingent earn-out obligation adjustment and an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.

    In connection with the acquisition of HCP, we recorded a receivable to offset potential tax liabilities. We reduced this asset during the third quarter of 2013 which negatively impacted operating income by $7.7 millionand is included in our general and administrative expenses. The reduction in operating income was directly offset by a corresponding reduction in income tax expense. This asset may be similarly reduced in the future if the underlying tax liabilities are no longer required.

    Adjusted operating income for the three and nine months ended September 30, 2012 was $344 million and$1.00 billion, respectively, which is operating income adjusted for transaction expenses associated with the acquisition of HCP and a legal settlement and related expenses.
  • Operating Income: Operating income for the three and nine months ended September 30, 2013 was $377 million and $1.07 billion, respectively.

    Operating income for the three and nine months ended September 30, 2012 was $341 million and $909 million, respectively.
  • Volume: Total U.S. dialysis treatments for the third quarter of 2013 were 6,034,647, or 76,388 treatments per day, representing a per day increase of 7.3% over the third quarter of 2012. Non-acquired treatment growth in the quarter was 5.5% over the third quarter of 2012. Normalized non-acquired treatment growth in the quarter was 5.4% over the third quarter of 2012.

    The number of member months for which HCP provided capitated care during the third quarter of 2013 was approximately 2.2 million representing an increase of 15.3% as compared to the third quarter of 2012, inclusive of growth contributed from acquisitions. These calculations include data prior to our merger with HCP onNovember 1, 2012.
  • Effective Tax Rate: Our effective tax rate was 37.3% and 32.9% for the three and nine months endedSeptember 30, 2013, respectively. This effective tax rate is impacted by the amount of third party owners’ income attributable to non-tax paying entities. The effective tax rate attributable to DaVita HealthCare Partners Inc. was 42.5% and 37.5% for the three and nine months ended September 30, 2013, respectively. The effective tax rate attributable to DaVita HealthCare Partners Inc. for the three and nine months endedSeptember 30, 2013, excluding a contingent earn-out obligation adjustment, a loss contingency reserve and an income tax adjustment related to the reduction in a tax asset associated with the HCP acquisition escrow provisions, was 38.3% and 39.5%, respectively.

    We expect our 2013 effective tax rate attributable to DaVita HealthCare Partners Inc. to be in the range of 38.0% to 39.0%. In addition, we expect our 2013 effective tax rate attributable to DaVita HealthCare Partners Inc. excluding a contingent earn-out obligation adjustment, a loss contingency reserve and the income tax adjustment related to a reduction in a tax asset associated with the HCP acquisition escrow provisions to be in the range of 39.0% to 40.0%.
  • Loss Contingency Reserve: We are engaged in good faith discussions with the attorneys from the United States Attorney’s Office for the District of Colorado, the Civil Division of the United States Department of Justiceand the Office of the Inspector General in an effort to find a mutually acceptable resolution to the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. Discussions have advanced to a point where we believed it was appropriate to accrue an additional $97 million to our estimated loss contingency reserve in the current quarter, which brings the total estimated loss contingency reserve to $397 million as of September 30, 2013, in connection with offers to settle the related civil, administrative and criminal matters. However, the discussions are ongoing, and until concluded, there can be no certainty about the timing or likelihood of a definitive resolution or the scope of any potential restrictions or impact on future operations that may be agreed upon in connection with a settlement. As these discussions proceed and additional information becomes available to us, the amount of the estimated loss contingency reserve may need to be adjusted further to reflect this new information.
  • Stock Split: In the third quarter of 2013, the Board of Directors approved a two-for-one stock split of our common stock in the form of a stock dividend payable on September 6, 2013 to stockholders of record onAugust 23, 2013. Our common stock began trading on a post-split basis on September 9, 2013. All share and per share data for all periods presented have been adjusted to reflect the effects of the stock split.
  • Contingent Earn-out Obligation: During the third quarter of 2013, we reached agreement with the representative of the former owners and option holders of HealthCare Partners Holdings, LLC (HCP) to settle certain post-closing adjustments, including the 2013 contingent earn-out obligation for $68.8 million, an amount equal to its carrying value at June 30, 2013. Accordingly, this settlement had no impact to our consolidated statements of income during the third quarter of 2013.
  • Center Activity: As of September 30, 2013, we provided dialysis services to a total of approximately 166,000 patients at 2,108 outpatient dialysis centers, of which 2,042 centers are located in the United States and 66 centers are located in ten countries outside of the United States. During the third quarter of 2013, we acquired 10 dialysis centers and opened a total of 25 dialysis centers in the United States. We also acquired 18 dialysis centers outside of the United States.

Outlook

  • We are narrowing our consolidated income guidance for 2013 to now be in the range of $1.88 billion to $1.92 billion. Our previous consolidated operating income guidance for 2013 was in the range of $1.83 billion to $1.93 billion.
  • We are updating our operating income guidance for our dialysis services and related ancillary businesses for 2013 to now be in the range of $1.50 billion to $1.52 billion. Our previous operating income guidance for 2013 was in the range of $1.45 billion to $1.50 billion.
  • We are also narrowing our operating income guidance for HCP for 2013 to now be in the range of $380 million to $400 million. Our previous operating income guidance for HCP for 2013 was in the range of $380 million to $430 million.
  • We are also updating our consolidated operating cash flow guidance for 2013 to now be in the range of $1.60 billion to $1.70 billion. Our previous consolidated operating cash flow guidance for 2013 was in the range of$1.40 billion to $1.50 billion.

The consolidated and dialysis services and related ancillary businesses operating income guidance amounts exclude an estimated loss contingency reserve of $397 million which we accrued during the first nine months of 2013 in connection with the 2010 and 2011 U.S. Attorney Physician Relationship Investigations and the consolidated cash flow guidance amounts exclude any potential payment of this reserve. In addition, the consolidated operating income guidance amounts exclude a contingent earn-out obligation adjustment of approximately $57 million that we recorded in the second quarter of 2013 related to the remeasurement of the fair value of HCP’s 2013 contingent earn-out obligation and excludes the adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions that was established as a receivable to offset any potential tax liabilities. These projections and the underlying assumptions involve significant risks and uncertainties, including those described below and actual results may vary significantly from these current projections.

We will be holding a conference call to discuss our results for the third quarter ended September 30, 2013 on November 5, 2013 at 5:00 p.m. Eastern Time. The dial in number for the U.S. is (800) 399-4406 and for international is (937) 528-2121. A replay of the conference call will be available on DaVita’s official web page, www.davita.com, for the following 30 days.

This release contains forward-looking statements within the meaning of the federal securities laws, including statements related to our guidance and expectations for our 2013 consolidated and dialysis services and related ancillary businesses operating income, HCP’s 2013 operating income, our 2013 operating cash flows and our 2013 effective tax rate attributable to DaVita HealthCare Partners Inc.Factors that could impact future results include the uncertainties associated with the risk factors set forth in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2012, our quarterly report on Form 10-Q for the quarter ended June 30, 2013 and subsequent quarterly reports to be filed on Form 10-Q, or our current reports on Form 8-K. The forward-looking statements should be considered in light of these risks and uncertainties.

These risks and uncertainties include, but are not limited to, and are qualified in their entirety by reference to the full text of those risk factors in our SEC filings relating to:

  • the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number of patients under such plans, which may result in the loss of revenues or patients,
  • a reduction in government payment rates under the Medicare End Stage Renal Disease program or other government-based programs,
  • the impact of health care reform legislation that was enacted in the United States in March 2010,
  • the impact of the Center for Medicare and Medicaid Services (CMS) 2014 Medicare Advantage benchmark structure,
  • the impact of the American Taxpayer Relief Act,
  • the impact of the sequestration that went into effect on April 1, 2013,
  • the impact of disruptions in federal government operations and funding,
  • changes in pharmaceutical or anemia management practice patterns, payment policies, or pharmaceutical pricing,
  • legal compliance risks, including our continued compliance with complex government regulations and current or potential investigations by various government entities and related government or private-party proceedings, including risks relating to the resolution of the 2010 and 2011 U.S. Attorney Physician Relationship Investigations,
  • our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector, that may erode our patient base and reimbursement rates,
  • our ability to complete any acquisitions, mergers or dispositions that we might be considering or announce, or to integrate and successfully operate any business we may acquire or have acquired, including HCP, or to expand our operations and services to markets outside the United States,
  • risks arising from the use of accounting estimates, judgments and interpretations in our financial statements,
  • the risk that the cost of providing services under HCP’s agreements may exceed our compensation,
  • the risk that reductions in reimbursement rates, including Medicare Advantage rates, and future regulations may negatively impact HCP’s business, revenue and profitability,
  • the risk that HCP may not be able to successfully establish a presence in new geographic regions or successfully address competitive threats that could reduce its profitability,
  • the risk that a disruption in HCP’s healthcare provider networks could have an adverse effect on HCP’s business operations and profitability,
  • the risk that reductions in the quality ratings of health maintenance organization plan customers of HCP could have an adverse effect on HCP’s business, or
  • the risk that health plans that acquire health maintenance organizations may not be willing to contract with HCP or may be willing to contract only on less favorable terms.

We base our forward-looking statements on information currently available to us at the time of this release, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

This release contains non-GAAP financial measures. For reconciliations of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see the attached reconciliation schedules. For the reasons stated in the reconciliation schedules, we believe our presentation of non-GAAP financial measures provides useful supplemental information for investors.

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(dollars in thousands, except per share data)

       
  Three months ended

September 30,

  Nine months ended
September 30,
    2013       2012       2013       2012  
Patient service revenues $ 2,126,699     $ 1,842,853     $ 6,155,223     $ 5,422,100  
Less: Provision for uncollectible accounts   (74,477 )     (59,822 )     (216,725 )     (167,268 )
Net patient service revenues   2,052,222       1,783,031       5,938,498       5,254,832  
Capitated revenues   747,264       16,362       2,219,953       44,894  
Other revenues   200,100       146,495       542,390       408,701  
Total net revenues   2,999,586       1,945,888       8,700,841       5,708,427  
Operating expenses and charges:              
Patient care costs and other costs   2,095,334       1,327,373       6,070,545       3,876,090  
General and administrative   305,138       197,912       857,658       616,106  
Depreciation and amortization   132,765       80,100       389,263       232,691  
Provision for uncollectible accounts   1,498       1,390       3,636       3,534  
Equity investment income   (9,223 )     (3,064 )     (26,239 )     (8,314 )
Loss contingency reserve and other legal settlements   97,000       1,292       397,000       79,292  
Contingent earn-out obligation adjustment

 

    (56,977 )  
Total operating expenses and charges   2,622,512       1,605,003       7,634,886       4,799,399  
Operating income   377,074       340,885       1,065,955       909,028  
Debt expense   (108,421 )     (70,494 )     (322,334 )     (192,584 )
Other income, net   2,113       819       1,337       2,698  
Income from continuing operations before income taxes   270,766       271,210       744,958       719,142  
Income tax expense   100,930       98,647       245,266       261,943  
Income from continuing operations   169,836       172,563       499,692       457,199  
Discontinued operations:              
(Loss) income from operations of discontinued operations, net of tax     (13 )     (139 )     238  
Gain on disposal of discontinued operations, net of tax       13,375    
Net income   169,836       172,550       512,928       457,437  
Less: Net income attributable to noncontrolling interests   (33,208 )     (27,829 )     (91,760 )     (77,259 )
Net income attributable to DaVita HealthCare Partners Inc. $ 136,628     $ 144,721     $ 421,168     $ 380,178  
Earnings per share:              
Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc. $ 0.65     $ 0.76     $ 1.95     $ 2.01  
Basic net income per share attributable to DaVita HealthCare Partners Inc. $ 0.65     $ 0.76     $ 2.01     $ 2.02  
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. $ 0.64     $ 0.75     $ 1.90     $ 1.98  
Diluted net income per share attributable to DaVita HealthCare Partners Inc. $ 0.64     $ 0.75     $ 1.96     $ 1.98  
Weighted average shares for earnings per share:              
Basic   210,394,560       189,959,716       209,725,439       188,618,198  
Diluted   214,902,860       193,269,240       214,631,587       192,248,452  
Amounts attributable to DaVita HealthCare Partners Inc.:              
Income from continuing operations $ 136,628     $ 144,726     $ 407,919     $ 379,953  
Discontinued operations     (5 )     13,249       225  
Net income $ 136,628     $ 144,721     $ 421,168     $ 380,178  
                               

 

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(unaudited)

(dollars in thousands)

       
  Three months ended

September 30,

  Nine months ended
September 30,
    2013       2012       2013       2012  
Net income $ 169,836     $ 172,550     $ 512,928     $ 457,437  
Other comprehensive income (loss), net of tax:              
Unrealized gain (loss) on interest rate swap and cap agreements:              
Unrealized (loss) gain on interest rate swap and cap agreements   (7,733 )     (1,741 )     1,583       (6,104 )
Reclassifications of net swap and cap agreements realized loss into net income   3,464       2,530       9,433       7,586  
Unrealized gains on investments:              
Unrealized gain on investments   648       445       1,367       1,387  
Reclassification of net investment realized gains into net income       (94 )     (75 )
Foreign currency translation adjustments   2,741       (135 )     (1,206 )     (1,593 )
Other comprehensive (loss) income   (880 )     1,099       11,083       1,201  
Total comprehensive income   168,956       173,649       524,011       458,638  
Less: Comprehensive income attributable to noncontrolling interests   (33,208 )     (27,829 )     (91,760 )     (77,259 )
Comprehensive income attributable to DaVita HealthCare Partners Inc. $ 135,748     $ 145,820     $ 432,251     $ 381,379  
                               

 

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)

   
  Nine months ended
September 30,
    2013       2012  
Cash flows from operating activities:      
Net income $ 512,928     $ 457,437  
Adjustments to reconcile net income to cash provided by operating activities:      
Loss contingency reserve   397,000    
Depreciation and amortization   389,387       234,368  
Stock-based compensation expense   47,095       34,857  
Tax benefits from stock award exercises   40,870       60,252  
Excess tax benefits from stock award exercises   (31,722 )     (39,346 )
Deferred income taxes   (52,085 )     (1,374 )
Equity investment income, net   1,074       10  
Other non-cash (income) charges and loss on disposal of assets   (54,203 )     17,244  
Changes in operating assets and liabilities, other than from acquisitions and divestitures:      
Accounts receivable   20,856       (51,349 )
Inventories   (5,494 )     1,958  
Other receivables and other current assets   (35,757 )     65,047  
Other long-term assets   17,861       3,429  
Accounts payable   (71,581 )     (18,200 )
Accrued compensation and benefits   114,877       113,101  
Other current liabilities   91,503       87,223  
Income taxes   (15,212 )     (69,108 )
Other long-term liabilities   51,757       5,064  
Net cash provided by operating activities   1,419,154       900,613  
Cash flows from investing activities:      
Additions of property and equipment, net   (399,527 )     (378,949 )
Acquisitions   (234,802 )     (419,114 )
Proceeds from asset and business sales   62,282       2,118  
Purchase of investments available for sale   (6,630 )     (3,452 )
Purchase of investments held-to-maturity   (1,034 )     (5,257 )
Proceeds from sale of investments available for sale   1,091       6,796  
Proceeds from maturities of investments held-to-maturity   1,376       12,375  
Purchase of intangible assets   (53 )     (1,276 )
Distributions received on equity investments   211       2  
Net cash used in investing activities   (577,086 )     (786,757 )
Cash flows from financing activities:      
Borrowings   49,941,883       26,992,105  
Payments on long-term debt, contingent obligations and other financing costs   (50,326,174 )     (25,821,996 )
Restricted cash   -       (1,268,767 )
Distributions to noncontrolling interests   (99,736 )     (81,978 )
Stock award exercises and other share issuances, net   12,432       8,395  
Excess tax benefits from stock award exercises   31,722       39,346  
Contributions from noncontrolling interests   30,041       19,368  
Proceeds from sales of additional noncontrolling interests   6,083       1,844  
Purchases from noncontrolling interests   (474 )     (13,774 )
Net cash used in financing activities   (404,223 )     (125,457 )
Effect of exchange rate changes on cash and cash equivalents   (899 )     43  
Net increase (decrease) in cash and cash equivalents   436,946       (11,558 )
Cash and cash equivalents at beginning of period   533,748       393,752  
Cash and cash equivalents at end of period $ 970,694     $ 382,194  
               

 

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(dollars in thousands, except per share data)

       
  September 30,
2013
  December 31,
2012
ASSETS      
Cash and cash equivalents $ 970,694     $ 533,748  
Short-term investments   6,796       7,138  
Accounts receivable, less allowance of $221,602 and $245,122   1,404,050       1,424,303  
Inventories   84,899       78,126  
Other receivables   295,540       265,671  
Other current assets   156,940       201,572  
Income tax receivable   64,351       55,454  
Deferred income taxes   398,138       315,782  
Total current assets   3,381,408       2,881,794  
Property and equipment, net of accumulated depreciation of $1,699,441 and $1,522,183   2,048,235       1,872,370  
Intangibles, net of accumulated amortization of $438,611 and $304,323   2,059,568       2,128,118  
Equity investments   41,465       35,150  
Long-term investments   72,568       59,341  
Other long-term assets   79,833       79,854  
Goodwill   9,144,242       8,952,987  
  $ 16,827,319     $ 16,009,614  
LIABILITIES AND EQUITY      
Accounts payable $ 358,402     $ 414,143  
Other liabilities   481,840       568,616  
Accrued compensation and benefits   685,352       566,911  
Medical payables   270,762       238,964  
Loss contingency reserve   397,000        
Current portion of long-term debt   259,770       227,791  
Total current liabilities   2,453,126       2,016,425  
Long-term debt   8,181,434       8,326,534  
Other long-term liabilities   353,723       443,743  
Alliance and product supply agreement, net   10,660       14,657  
Deferred income taxes   769,713       710,638  
Total liabilities   11,768,656       11,511,997  
Commitments and contingencies      
Noncontrolling interests subject to put provisions   621,232       580,692  
Equity:      
Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)      
Common stock ($0.001 par value, 450,000,000 shares authorized; 212,671,800 shares issued and outstanding at September 30, 2013; 269,724,566 shares issued and 210,997,150 shares outstanding at December 31, 2012)   213       270  
Additional paid-in capital   1,120,276       1,208,665  
Retained earnings   3,151,711       3,731,835  
Treasury stock, at cost (58,727,416 shares at December 31, 2012)         (1,162,336 )
Accumulated other comprehensive loss   (4,214 )     (15,297 )
Total DaVita HealthCare Partners Inc. shareholders’ equity   4,267,986       3,763,137  
Noncontrolling interests not subject to put provisions   169,445       153,788  
Total equity   4,437,431       3,916,925  
  $ 16,827,319     $ 16,009,614  
               

 

DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA

(unaudited)

(dollars in millions, except for per share and per treatment data)

         
  Three months ended    

Nine months
ended

September 30,
2013

  September 30,

2013

  June 30,

2013

  September 30,

2012

   
1. Consolidated Financial Results:                
Consolidated net revenues $ 3,000     $ 2,872     $ 1,946     $ 8,701  
Operating income $ 377.1     $ 522.0     $ 340.9     $ 1,066.0  
Operating income margin   12.6 %     18.2 %     17.5 %     12.3 %
Operating income excluding a contingent earn-out obligation adjustment, a loss contingency reserve, an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions, transaction expenses associated with the acquisition of HCP and a legal settlement and related expenses(1) $ 481.8     $ 465.0     $ 343.5     $ 1,413.7  
Operating income margin excluding a contingent earn-out obligation adjustment, a loss contingency reserve, an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions, transaction expenses associated with the acquisition of HCP and a legal settlement and related expenses(1)   16.1 %     16.2 %     17.7 %     16.2 %
Income from continuing operations attributable to DaVita HealthCare Partners Inc. $ 136.6     $ 254.4     $ 144.7     $ 407.9  
Income from continuing operations attributable to DaVita HealthCare Partners Inc. excluding a contingent earn-out obligation adjustment, a loss contingency reserve, transaction expenses associated with the acquisition of HCP, debt refinancing charges and a legal settlement and related expenses, which are all net of related tax(1) $ 211.0     $ 197.4     $ 147.5     $ 605.3  
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. $ 0.64     $ 1.18     $ 0.75     $ 1.90  
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. excluding a contingent earn-out obligation adjustment, a loss contingency reserve, transaction expenses associated with the acquisition of HCP, debt refinancing charges and a legal settlement and related expenses, which are all net of related tax(1) $ 0.98     $ 0.92     $ 0.76     $ 2.82  
Adjusted diluted income from continuing operations attributable to DaVita HealthCare Partners Inc(1) $ 235.7     $ 221.5     $ 151.5     $ 678.1  
Adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.(1) $ 1.10     $ 1.03     $ 0.78     $ 3.16  
                 
2. Consolidated Business Metrics:                
Expenses                
General and administrative expenses as a percent of consolidated net revenues(2)   10.2 %     9.3 %     10.2 %     9.9 %
Consolidated effective tax rate   37.3 %     31.3 %     36.4 %     32.9 %
Consolidated effective tax rate attributable to DaVita HealthCare Partners Inc.(1)   42.5 %     33.6 %     40.5 %     37.5 %
                 
3. Summary of Segment Financial Results:                
Net revenues                
Net dialysis and related lab services revenues $ 1,983     $ 1,922     $ 1,785     $ 5,757  
Net HCP revenues   803       761           2,367  
Net ancillary services and strategic initiatives revenues   226       200       167       610  
Total net segment revenues   3,012       2,883       1,952       8,734  
Elimination of intersegment revenues   (12 )     (11 )     (6 )     (33 )
Total net consolidated revenues $ 3,000     $ 2,872     $ 1,946     $ 8,701  
                               

 

DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA—continued

(unaudited)

(dollars in millions, except for per share and per treatment data)

               
  Three months ended    

Nine months
ended

September 30,
2013

 
  September 30,

2013

  June 30,

2013

    September 30,

2012

     
3. Segment Financial Results: (continued)                    
Operating income                    
Dialysis and related lab services operating income $ 309     $ 404     $ 367     $ 800  
HCP operating income   98       81           287  
Other – Ancillary services and strategic initiatives, including international dialysis operations operating losses   (9 )     (7 )     (13 )     (31 )
Total segment operating income   398       478       354       1,056  
Reconciling items:                    
Contingent earn-out obligation adjustment

    57    

      57  
Corporate support and related long-term incentive compensation   (13 )     (13 )     (12 )     (39 )
Transaction expenses and the adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions   (8 )         (1 )     (8 )
Consolidated operating income $ 377     $ 522     $ 341     $ 1,066  
Dialysis and Related Lab Services                    
Revenue:                    
Patient services revenues $ 2,052     $ 1,988     $ 1,842     $ 5,956  
Provision for uncollectible accounts   (72 )     (69 )     (60 )     (208 )
Net patient service operating revenues   1,980       1,919       1,782       5,748  
Other revenues   3       3       3       9  
Total net operating revenues $ 1,983     $ 1,922     $ 1,785     $ 5,757  
Operating expenses:                    
Patient care cost $ 1,311     $ 1,265     $ 1,188     $ 3,792  
General and administrative   180       167       154       514  
Depreciation and amortization   89       89       78       263  
Equity investment income   (3 )     (3 )     (3 )     (9 )
Loss contingency reserve and a legal settlement and related expenses   97    

      1       397  
Total operating expenses   1,674       1,518       1,418       4,957  
Segment operating income $ 309     $ 404     $ 367     $ 800  
HCP                    
Revenue:                    
HCP capitated revenues $ 731     $ 693     $ ─     $ 2,169  
Patient services revenues   61       52           169  
Provision for uncollectible accounts   (3 )     (3 )         (8 )
Net patient service operating revenues   58       49           161  
Other revenues   14       19           37  
Total net operating revenues $ 803     $ 761     $ ─     $ 2,367  
Operating expenses:                    
Patient care cost $ 605     $ 590     $ ─     $ 1,789  
General and administrative   67       56           192  
Depreciation and amortization   39       39           116  
Equity investment income   (6 )     (5 )         (17 )
Total operating expenses   705       680           2,080  
Segment operating income $ 98     $ 81     $ ─     $ 287  
                             

 

DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA—continued

(unaudited)

(dollars in millions, except for per share and per treatment data)

       
  Three months ended  

Nine months
ended

September 30,
2013

  September 30,

2013

  June 30,

2013

  September 30,

2012

 
4. Dialysis and Related Lab Services Business Metrics:              
Volume              
Treatments   6,034,647       5,867,973       5,550,645       17,531,419  
Number of treatment days   79.0       78.0       78.0       233.5  
Treatments per day   76,388       75,230       71,162       75,081  
Per day year over year increase   7.3 %     7.6 %     12.3 %     7.7 %
Non-acquired growth year over year   5.5 %     5.0 %     4.4 %     5.0 %
Operating revenues before provision for uncollectible accounts              
Dialysis and related lab services revenue per treatment $ 339.99     $ 338.86     $ 331.93     $ 339.76  
Per treatment increase (decrease) from previous quarter   0.3 %     (0.5 %)     (0.2 %)  
Per treatment increase (decrease) from previous year   2.4 %     1.9 %     (0.6 %)     2.2 %
Percent of net consolidated revenues   65.8 %     66.6 %     91.5 %     65.9 %
               
Expenses              
Patient care costs              
Percent of total segment operating revenues   66.1 %     65.8 %     66.5 %     65.9 %
Per treatment $ 217.15     $ 215.66     $ 214.03     $ 216.29  
Per treatment increase (decrease) from previous quarter   0.7 %     (0.2 %)     0.1 %  
Per treatment increase (decrease) from previous year   1.5 %     0.9 %     (0.8 %)     1.3 %
General and administrative expenses              
Percent of total segment operating revenues   9.1 %     8.7 %     8.6 %     8.9 %
Per treatment $ 29.83     $ 28.42     $ 27.72     $ 29.32  
Per treatment increase (decrease) from previous quarter   5.0 %     (4.3 %)     (2.0 %)  
Per treatment increase (decrease) from previous year   7.6 %     0.5 %     (4.6 %)     2.7 %
Accounts receivable              
Net receivables $ 1,105     $ 1,117     $ 1,200     $ ─
DSO   52       54       62    
Provision for uncollectible accounts as a percentage of net revenues   3.5 %     3.5 %     3.2 %     3.5 %
               
5. HCP Business Metrics:              
Capitated membership              
Total   760,000       733,000      
Member months   2,236,700       2,209,000         6,685,100  
Capitated revenues by sources              
Commercial revenues $ 176     $ 176     $ ─   $ 533  
Senior revenues   539       496         1,587  
Medicaid revenues   16       21         49  
Total capitated revenues $ 731     $ 693     $ ─   $ 2,169  
Other              
Total care dollars under management(1) $ 1,037     $ 997       $ 3,077  
Ratio of operating income to total care dollars under management   9.4 %     8.2 %       9.3 %
Full time clinicians   1,200       1,073      
IPA primary care physicians   2,999       2,846      
                       

 

DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA—continued

(unaudited)

(dollars in millions, except for per share and per treatment data)

   
           
  Three months ended  

 

Nine months
ended

September 30,
2013

 
  September 30,

2013

  June 30,

2013

  September 30,

2012

   
6. Cash Flow:                  
Operating cash flow $ 733.1     $ 306.8     $ 366.6     $ 1,419.2  
Operating cash flow, last twelve months $ 1,619.4     $ 1,252.9     $ 1,051.3    

$

 
Free cash flow(1) $ 643.2     $ 218.3     $ 271.4     $ 1,160.3  
Free cash flow, last twelve months(1) $ 1,243.0     $ 871.2     $ 664.8    

$

 
Capital expenditures:                  
Routine maintenance/IT/other $ 55.4     $ 58.3     $ 63.7     $ 159.1  
Development and relocations $ 85.7     $ 83.4     $ 64.7     $ 240.4  
Acquisition expenditures $ 82.7     $ 60.6     $ 72.3     $ 234.8  
                   
7. Debt and Capital Structure:                  
Total debt(3) $ 8,460     $ 8,496     $ 5,745          
Net debt, net of cash and cash equivalents(3) $ 7,489     $ 7,878     $ 4,094          
Leverage ratio (see calculation on page 13) 3.16x   3.39x   2.61x        
Overall weighted average effective interest rate during the quarter   4.87 %     4.86 %     5.31 %        
Overall weighted average effective interest rate at end of the quarter   4.86 %     4.85 %     5.38 %        
Weighted average effective interest rate on the Senior Secured Credit Facilities at end of the quarter   4.18 %     4.18 %     4.61 %        
Fixed and economically fixed interest rates as a percentage of our total debt(4)   60 %     61 %     66 %        
Fixed and economically fixed interest rates, including our interest rate cap agreements, as a percentage of our total debt(4)   93 %     93 %     88 %        
                   
8. Clinical: (quarterly averages)                  
Dialysis adequacy -% of patients with Kt/V > 1.2 at the end of the quarter   98 %     98 %     98 %        
Dialysis patients with arteriovenous fistulas placed   72 %     72 %     71 %        

_________________

(1) These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see attached reconciliation schedules.

(2) Consolidated percentages of revenues are comprised of the dialysis and related lab services business, HCP’s business and other ancillary services and strategic initiatives, and in case of general and administrative expenses, includes other certain corporate support and related long-term incentive compensation and transaction expenses associated with the acquisition of HCP.

(3) The reported balance sheet amounts at September 30, 2013June 30, 2013 and September 30, 2012, exclude $18.6 million$19.6 million and $6.6 million, respectively, of debt discounts associated with our Term Loan B, Term Loan B-2 and our Term Loan A-2.

(4) The Term Loan B and Term Loan B-2 are subject to LIBOR floors of 1.50% and 1.00%, respectively. Because actual LIBOR, for all periods presented above, was lower than either of these embedded LIBOR floors, the interest rates on the Term Loan B and the Term Loan B-2 are set at their respective floors. At such time as the actual LIBOR-based variable component of our interest rate exceeds 1.50% on the Term Loan B and 1.00% on the Term Loan B-2, we will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of our interest rate on all of the Term Loan B, as well as for the Term Loan B-2. However, we are limited to a maximum rate of 2.50% on $1.25 billion of outstanding principal debt on the Term Loan B and $1.49 billion of outstanding principal debt on the Term Loan B-2 as a result of interest rate cap agreements. The remaining $452 million outstanding principal balance of the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 1.50%. The remaining $153 million outstanding principal balance of the Term Loan B-2 is subject to LIBOR-based interest rate volatility above a floor of 1.00%.

DAVITA HEALTHCARE PARTNERS INC.
SUPPLEMENTAL FINANCIAL DATA—continued
(unaudited)
(dollars in thousands)

Note 1: Calculation of the Leverage Ratio

Under the Senior Secured Credit Facilities (Credit Agreement), the leverage ratio is defined as all funded debt plus the face amount of all letters of credit issued, minus cash and cash equivalents, divided by “Consolidated EBITDA”. The leverage ratio determines the interest rate margin payable by the Company for its Term Loan A and revolving line of credit under the Credit Agreement by establishing the margin over the base interest rate (LIBOR) that is applicable. The following leverage ratio was calculated using “Consolidated EBITDA” as defined in the Credit Agreement. The calculation below is based on the last twelve months of “Consolidated EBITDA”, pro forma for routine acquisitions that occurred during the period. The Company’s management believes the presentation of “Consolidated EBITDA” is useful to investors to enhance their understanding of the Company’s leverage ratio under its Credit Agreement.

  Rolling twelve months ended

September 30, 2013

 
Net income attributable to DaVita HealthCare Partners Inc. $ 577,007  
Income taxes   343,168  
Interest expense and debt refinancing charges   399,404  
Depreciation and amortization   498,541  
Loss contingency reserve   397,000  
Noncontrolling interests and equity investment income, net   124,169  
Stock-based compensation   57,375  
Other (primarily pro-forma EBITDA on acquisitions)   46,927  
“Consolidated EBITDA” $ 2,443,591  
     
  September 30, 2013  
Total debt, excluding debt discount of $18.6 million $ 8,459,843  
Letters of credit issued   99,693  
    8,559,536  
Less: Cash and cash equivalents   (847,833 )
Consolidated net debt $ 7,711,703  
Last twelve months “Consolidated EBITDA” $ 2,443,591  
Leverage ratio 3.16x  

In accordance with the Credit Agreement, the Company’s leverage ratio cannot exceed 5.00 to 1.00 as of September 30, 2013. At that date the Company’s leverage ratio did not exceed 5.00 to 1.00.

DAVITA HEALTHCARE PARTNERS INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in thousands except for per share data)

1. Income from continuing operations and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. excluding a contingent earn-out obligation adjustment, a loss contingency reserve, transaction expenses associated with the acquisition of HCP, debt refinancing charges and a legal settlement and related expenses, which are all net of related tax.

We believe that income from continuing operations attributable to DaVita HealthCare Partners Inc.excluding a contingent earn-out obligation adjustment, a loss contingency reserve, transaction expenses associated with the acquisition of HCP, debt refinancing charges and a legal settlement and related expenses, which are all net of related tax, enhances a user’s understanding of our normal income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. for these periods by providing a measure that is meaningful because it excludes unusual amounts that include an adjustment to HCP’s contingent earn-out obligation, a loss contingency reserve related to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations, transaction expenses associated with the acquisition of HCP, debt refinancing charges related to the amendment of our credit agreement and the repayment of our Term Loan A-2, and legal expenses associated with a legal settlement that we reached to settle federal program claims relating to our historical Epogen practices and accordingly, is comparable to prior periods and indicative of consistent income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. These measures are not measures of financial performance under United States generally accepted accounting principles (GAAP) and should not be considered as an alternative to income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

Income from continuing operations attributable to DaVita HealthCare Partners Inc. excluding a contingent earn-out obligation adjustment, a loss contingency reserve, transaction expenses associated with the acquisition of HCP, debt refinancing charges and a legal settlement and related expenses, which are all net of related tax: Three months ended     Nine months ended  
  September 30,

2013

    June 30,

2013

  September 30,

2012

    September 30,

2013

    September 30,

2012

 
Income from continuing operations attributable to DaVita HealthCare Partners Inc. $ 136,628     $ 254,376     $ 144,726     $ 407,919     $ 379,953  
Add (Subtract):                          
Contingent earn-out obligation adjustment       (56,977 )         (56,977 )    
Loss contingency reserve   97,000             397,000      
Transaction expenses associated with the acquisition of HCP         1,335           17,771  
Debt refinancing charges         2,062           2,062  
Legal settlement and related expenses         1,292           79,292  
Less: Related income tax   (22,650 )       (1,899 )     (142,650 )    

(40,443

)

  $ 210,978     $ 197,399     $ 147,516     $ 605,292     $ 438,635  
                                       

 

DAVITA HEALTHCARE PARTNERS INC.

RECONCILIATIONS FOR NON-GAAP MEASURES – (continued)

(unaudited)

(dollars in thousands except for per share data)

         
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. excluding a contingent earn-out obligation adjustment, a loss contingency reserve, transaction expenses associated with the acquisition of HCP, debt refinancing charges and a legal settlement and related expenses, which are all net of related tax: Three months ended   Nine months ended
  September 30,

2013

  June 30,

2013

  September 30,

2012

  September 30,

2013

  September 30,

2012

Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. $ 0.64   $ 1.18     $ 0.75   $ 1.90     $ 1.98
Add (Subtract):                  
Contingent earn-out obligation adjustment     (0.26 )       (0.26 )  
Loss contingency reserve   0.34         1.18    
Transaction expenses associated with the acquisition of HCP           0.05
Debt refinancing charges       0.01       0.01
Legal settlement and related expenses           0.24
  $ 0.98   $ 0.92     $ 0.76   $ 2.82     $ 2.28
                   

DAVITA HEALTHCARE PARTNERS INC.
RECONCILIATIONS FOR NON-GAAP MEASURES – (continued)
(unaudited)
(dollars in thousands except for per share data)

In addition, we have excluded amortization of intangible assets associated with acquisitions from our adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. and from our adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. as we believe this presentation enhances a user’s understanding of our operating results for these periods by providing an accurate reflection of the Company’s operating performance since it excludes the amortization of intangible assets that relate to the remeasurement of acquired intangible assets associated with our acquisitions to fair value, and accordingly is indicative of consistent income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.These measures are not measures of financial performance under GAAP and should not be considered as an alternative to income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

Adjusted income from continuing operations and adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc., further adjusted to exclude the amortization of intangible assets associated with acquisitions: Three months ended     Nine months ended  
  September 30,

2013

  June 30,

2013

  September 30,

2012

    September 30,

2013

  September 30,

2012

 
Adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. $ 210,978     $ 197,399     $ 147,516     $ 605,292     $ 438,635  
Add:                      
Amortization of intangible assets associated with acquisitions for the dialysis and ancillary operations   6,918       6,827       6,729       20,627       19,913  
Amortization of intangible assets associated with acquisitions for the HCP operations   33,230       33,088           99,680      
Related income tax   (15,377 )     (15,767 )     (2,725 )     (47,522 )     (8,132 )
  $ 235,749     $ 221,547     $ 151,520     $ 678,077     $ 450,416  
                       
Adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. $ 0.98     $ 0.92     $ 0.76     $ 2.82     $ 2.28  
Add:                      
Amortization of intangible assets per share associated with acquisitions for the dialysis and ancillary operations, net of tax   0.02       0.02       0.02       0.06       0.06  
Amortization of intangible assets per share associated with acquisitions for the HCP operations, net of tax   0.10       0.09           0.28      
  $ 1.10     $ 1.03     $ 0.78     $ 3.16     $ 2.34  
                                       

DAVITA HEALTHCARE PARTNERS INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in thousands)

2. Operating income excluding a pre-tax contingent earn-out obligation adjustment, a pre-tax loss contingency reserve, pre-tax transaction expenses associated with the acquisition of HCP, a pre-tax legal settlement and related expenses and an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.

We believe that operating income excluding a pre-tax contingent earn-out obligation adjustment, a pre-tax loss contingency reserve, pre-tax transaction expenses associated with the acquisition of HCP, a pre-tax legal settlement and related expenses and an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions enhances a user’s understanding of our normal operating income for these periods by providing a measure that is meaningful because it excludes unusual amounts that include an adjustment for HCP’s contingent earn-out obligation, a loss contingency reserve related to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations, transaction expenses associated with the acquisition of HCP, legal settlement and related expenses to settle federal program claims relating to our historical Epogen practices and an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions that was established as a receivable to offset any potential tax liabilities, and accordingly, is comparable to prior periods and indicative of consistent operating income. This measure is not a measure of financial performance under GAAP and should not be considered as an alternative to operating income.

Operating income excluding a pre-tax contingent earn-out obligation adjustment, a pre-tax loss contingency reserve, pre-tax transaction expenses associated with the acquisition of HCP, a pre-tax legal settlement and related expenses and an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions: Three months ended   Nine months ended
  September 30,

2013

  June 30,

2013

  September 30,

2012

  September 30,

2013

  September 30,

2012

Operating income $ 377,074   $ 522,020     $ 340,885   $ 1,065,955     $ 909,028
Add (Subtract):                  
Contingent earn-out obligation adjustment     (56,977 )       (56,977 )  
Loss contingency reserve   97,000         397,000    
Transaction expenses associated with the acquisition of HCP       1,335       17,771
Legal settlement and related expenses       1,292       79,292
Adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions   7,721         7,721    
Adjusted operating income $ 481,795   $ 465,043     $ 343,512   $ 1,413,699     $ 1,006,091
                                 

DAVITA HEALTHCARE PARTNERS INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in thousands)

3. Effective Income Tax Rates

We believe that reporting the effective income tax rate attributable to DaVita HealthCare Partners Inc.as well as the adjusted effective income tax rate attributable to DaVita HealthCare Partners Inc., excluding a contingent earn-out obligation adjustment, a loss contingency reserve and an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions, enhances an investor’s understanding of DaVita HealthCare Partners Inc.’s effective income tax rate and DaVita HealthCare Partners Inc.’s adjusted effective income tax rate for the periods presented because it excludes noncontrolling owners’ income that primarily relates to non-tax paying entities, unusual amounts that include a contingent earn-out obligation adjustment, a loss contingency reserve related to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations and an income tax adjustment which is offset by a corresponding reduction in a tax asset associated with the HCP acquisition escrow provisions that was established as a receivable to offset any potential tax liabilities, and is meaningful to an investor to fully understand the related income tax effects on DaVita HealthCare Partners Inc.’s operating results. These are not measures under GAAP and should not be considered as an alternative to the effective income tax rate calculated in accordance with GAAP.

Effective income tax rate as compared to the effective income tax rate attributable to DaVita HealthCare Partners Inc. is as follows:

 

  Three months ended   Nine months

ended

September 30, 2013

  September 30,

2013

 

June 30,

2013

  September 30,

2012

 
Income from continuing operations before income taxes $ 270,766     $ 412,550     $ 271,210     $ 744,958  
Income tax expense $ 100,930     $